Odylia Therapeutics的动态

Finally out there ?? Our article on PK-PD of combined intranasal N,N-DMT & buccal harmine ??

As the general secretary of All. Can Romania, we were honored to host the wrap up meeting of the local All.Can initiative the other day gathering both its financing and scientific members. ??A major milestone has been thus checked for All.Can Romania, grasping the final conclusions on one of their key projects of 2024 - Improving the Financing Mechanisms of Oncological Care in Romania. Together with key technical managers from the Ministry of Finance and the National Institute of Health Services Management the debate focused on the current resource gaps in oncology in Romania and explored on how to overcome them contributing to a more efficient oncology system. ?? All. Can Romania forthcoming step next year targets policy makers engagement that will facilitate the implemantaion of the policy recommendations originating from the analysis conducted this year. ?? More details about the local initiative in the link below.

Just a reminder that David Heal of DevelRx Ltd will be attending the Safety Pharmacology Society Annual Meeting to be held at the Town and Country Resort, San Diego, California, USA, 22nd to 25th September 2024. Details of our posters are: David Heal, Jane Gosden, Sharon Smith. Discriminating Evidence – Use and Misuse of the Drug Discrimination Test in Abuse Potential Assessments of Novel CNS Drugs. Poster Number 026-C. David Heal, Jane Gosden, Sharon Smith. Intravenous Self-administration – Valid Experimental Designs to Evaluate the Abuse Potential of Psychedelics, Entactogens and Drugs with Novel Mechanisms. Poster Number 027-C. Poster presentation times are: 23rd September 2024. Poster Session 1. 3.00-3.45 pm. 24th September 2024. Poster Session 2. 9.15-10.00 am. Golden State Ballroom. David will also be describing the refinements to IVSA methodology required to test the new generation of CNS drugs (Poster 027) as an oral communication (Oral Communications 2. CNS/Respiratory. 23rd September 2.00-2.15 pm. Town & Country Ballroom D). If you would like to see David at the SPS meeting please get in touch or visit our posters. If your company is based in San Diego and you would like to see David while he is in the area please contact us via [email protected] #2024SPS #safetypharmacology #abusepotential #psychedelics #drugdevelopment https://lnkd.in/eE39PrPY

I learned from one of my previous managers (Andy Barlow) that it’s not important how many things you start, but how many things you finish. Now, after years, with the support of our leaders Priv.- Doz. Dr. med. Lukas Martin, MHBA and Georg Griesemann and the team Adrian Alexandru Chiper, Paula Filip, Balan Andrei Mihai, Adrian Manigutiu, Olguta Stanescu, Adrian Mosutiu, Catalin Bobolicu, we focus on getting the things done while looking into the future ??. Thanks ABC Incubator for hosting us! Clinomic Romania II Clinomic

?? Beacon Cytokine's #SITC 2024 Post Conference Report is here! ?? This year, SITC was held in Houston, Texas from 6-10th November, providing a host of exciting #data and #updates in the #immunotherapy for #cancer space. ?? The Beacon analyst team identified 114 cytokine-related abstracts (42 clinical, 67 preclinical & 5 trial outlines). Notable highlights included: ?? Of the 18 different cytokine-targeting approaches showcased, fusion proteins were the most studied, accounting for 16% of abstracts, followed closely by ICMs (15%) ?? IL-2 emerged as the most prominent #cytokine #target, primarily in #preclinical studies, with 17 abstracts presenting data on this target (9 preclinical, 8 #clinical) ?? 50% of the preclinical IL-2 abstracts combined IL-2 with #ICM targets like PD-1 and CTLA-4, suggesting a trend towards dual targeting cytokine and checkpoint pathways ?? IL-12 was the second most studied, included in 10 abstracts, seen in stand-alone trials and in combination, involving targets like IL-15, IL-17 and chemokines ?? Solid tumours represented the most frequently studied disease category, with #melanoma being the key indication ?? The E1609 trial was the only phase 3 study with data presented at SITC 2024, investigating Intron A as an adjuvant in cutaneous melanoma ?? The clear shift we are seeing towards cytokine therapies targeting solid tumour indications reflects the high unmet need in advanced cancers and melanoma's responsiveness to immune-based therapies. Together, this continues to drive research interest and resource allocation towards these indications and therapy types. How are you ensuring you don't miss any relevant abstracts from major conferences? See a snippet of how Beacon users collate this data below: https://lnkd.in/efzT6Ckr

ONE partner to address your Precision Medicine Oncology needs. Check out our posters and abstracts and schedule a meeting here or message me via DM if you'd like to meet. #Biomarkers #PrecisionMedicine #CDx #ctDNA #LiquidBiopsy #GenomicProfiling #ImmuneProfiling #ClinicalDevelopment #Commercialization

Iktos appoints new Scientific Advisory Board with

A New Theranostics Center of Excellence in Europe

?? BREAKING NEWS ?? Rovia is making headlines with an exciting announcement. Read the full story to learn more! Link below. #roviaclinicalresearch #eastcoastinstituteforresearch #universalaxonclinicalresearch #imicclinicalresearch #pathfinderstopossibilities

Drug discovery: P2X7 receptors are very promising therapeutic targets. This paper provides an atomic understanding of key modulation binding sites using Cryo-EM. Check it out.